Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ:FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a report ...

In a report released today, Matt Larew from William Blair maintained a Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Proficio Capital Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Ascendis Pharma A/S (ASND) shares rallied 10.4% in the last trading session to close at $168.84. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Repligen (NasdaqGS:RGEN) with a In-Line ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...